March 15, 2024 · Form 4 insider transaction
Dolan Matthew Vincent sold 1,314 shares of DexCom, Inc. at $130.77 per share, a transaction worth $171.8K. The trade was recorded as open-market sale and disclosed on an SEC Form 4, filed 4 days after the transaction.
On December 15, 2023, Mr. Dolan adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Dolan. The shares set forth above were sold pursuant to the 10b5-1 Plan.; This transaction was executed in multiple trades at prices ranging from $130.165 to $130.95. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.; Included in this number are 40,075 unvested restricted stock units, 21,711 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, and 3,852 of which were granted on March 8, 2022 and shall vest through March 8, 2025.